

When Intravenous Vancomycin Prophylaxis is Needed in Shoulder Arthroplasty, Incomplete Administration is Associated with Increased Infectious Complications

Erick M. Marigi¹, Ian Marigi, Harsh Shah, Bradley S Schoch, John William Sperling¹, Joaquin Sanchez-Sotelo¹
¹Mayo Clinic

INTRODUCTION: Vancomycin is often used as antimicrobial prophylaxis for shoulder arthroplasty (SA) either when first generation cephalosporins are contraindicated or colonization with resistant bacteria is anticipated. In general, vancomycin necessitates longer infusion times to mitigate potential side effects. When infusion is started too close to the time of the incision, administration may not be complete during surgery. This study evaluated whether incomplete administration of intravenous (IV) vancomycin prior to shoulder arthroplasty (SA) affects the rate of infectious complications.

METHODS: Between 2000 to 2019, all primary SA types (hemiarthroplasty, anatomic total shoulder arthroplasty, reverse shoulder arthroplasty) performed at a single institution for elective and trauma indications using IV vancomycin as the primary antibiotic prophylaxis and a minimum follow-up of 2 years were identified. The time between the initiation of vancomycin and skin incision was calculated. Complete administration was defined as at least 30 minutes of infusion prior to incision. Demographic characteristics and infectious complications including survival free of prosthetic joint infection (PJI) were generated. Multivariable analyses were conducted to evaluate the association between vancomycin timing and the development of PJI.

RESULTS:

A total of 461 primary SA were included. Infusion was complete (>30 minutes preoperatively) for 163 [35.4%] and incomplete (< 30 minutes preoperatively) for 298 [64.6%] SA. The incomplete group demonstrated higher rates of any infectious complication (8% vs. 2.3%; P = .005), PJI (5.5% vs. 1%; P = .004), and reoperation inclusive of revision due to infectious complications (4.9% vs. 1%; P = .009). Survivorship free of PJI was worse in SA with incomplete compared to those with complete vancomycin administration. Survival rates for incomplete and complete administration were 97.6% and 99.3% at 1 month, 95.7% and 99.0% at 2 years, 95.1% and 99.0% at 5 years, and 93.9% and 99.0% at 20 years, respectively (P = .006). Multivariable analyses confirmed that incomplete vancomycin administration was an independent risk factor for PJI compared with complete administration (hazard ratio [HR], 4.22 [95% confidence interval (CI), 1.12 to 15.90]; P = .033), even when other independent predictors of PJI (age, male sex, prior surgery, MRSA colonization, and follow-up) were considered.

DISCUSSION AND CONCLUSION:

When vancomycin is the primary prophylactic agent used at the time of primary shoulder arthroplasty, incomplete administration (infusion to incision time under 30 minutes) seems to adversely increase the rates of infectious complications and PJI. Prophylaxis protocols should ensure that complete vancomycin administration is achieved in order to minimize infection after SA.

Figure 1 Kaplan-Meier survival plot for PJI in IV vancomycin administration




Table 1 Demographic and Clinical Characteristics by IV Vancomycin Administration

Characteristic	Complete (n=163)	Incomplete (n=298)	P
Age (years)	68.5 (15.2)	68.5 (15.2)	.998
Male	80 (49.1%)	131 (43.9%)	.152
Female	83 (50.9%)	167 (56.1%)	
MI	11 (6.7%)	19 (6.4%)	.841
ASA	1.0 (0.0%)	1.0 (0.0%)	.999
ASA 1	163 (100%)	298 (100%)	
ASA 2	0 (0.0%)	0 (0.0%)	
ASA 3	0 (0.0%)	0 (0.0%)	
ASA 4	0 (0.0%)	0 (0.0%)	
ASA 5	0 (0.0%)	0 (0.0%)	
ASA 6	0 (0.0%)	0 (0.0%)	
ASA 7	0 (0.0%)	0 (0.0%)	
ASA 8	0 (0.0%)	0 (0.0%)	
ASA 9	0 (0.0%)	0 (0.0%)	
ASA 10	0 (0.0%)	0 (0.0%)	
ASA 11	0 (0.0%)	0 (0.0%)	
ASA 12	0 (0.0%)	0 (0.0%)	
ASA 13	0 (0.0%)	0 (0.0%)	
ASA 14	0 (0.0%)	0 (0.0%)	
ASA 15	0 (0.0%)	0 (0.0%)	
ASA 16	0 (0.0%)	0 (0.0%)	
ASA 17	0 (0.0%)	0 (0.0%)	
ASA 18	0 (0.0%)	0 (0.0%)	
ASA 19	0 (0.0%)	0 (0.0%)	
ASA 20	0 (0.0%)	0 (0.0%)	
ASA 21	0 (0.0%)	0 (0.0%)	
ASA 22	0 (0.0%)	0 (0.0%)	
ASA 23	0 (0.0%)	0 (0.0%)	
ASA 24	0 (0.0%)	0 (0.0%)	
ASA 25	0 (0.0%)	0 (0.0%)	
ASA 26	0 (0.0%)	0 (0.0%)	
ASA 27	0 (0.0%)	0 (0.0%)	
ASA 28	0 (0.0%)	0 (0.0%)	
ASA 29	0 (0.0%)	0 (0.0%)	
ASA 30	0 (0.0%)	0 (0.0%)	
ASA 31	0 (0.0%)	0 (0.0%)	
ASA 32	0 (0.0%)	0 (0.0%)	
ASA 33	0 (0.0%)	0 (0.0%)	
ASA 34	0 (0.0%)	0 (0.0%)	
ASA 35	0 (0.0%)	0 (0.0%)	
ASA 36	0 (0.0%)	0 (0.0%)	
ASA 37	0 (0.0%)	0 (0.0%)	
ASA 38	0 (0.0%)	0 (0.0%)	
ASA 39	0 (0.0%)	0 (0.0%)	
ASA 40	0 (0.0%)	0 (0.0%)	
ASA 41	0 (0.0%)	0 (0.0%)	
ASA 42	0 (0.0%)	0 (0.0%)	
ASA 43	0 (0.0%)	0 (0.0%)	
ASA 44	0 (0.0%)	0 (0.0%)	
ASA 45	0 (0.0%)	0 (0.0%)	
ASA 46	0 (0.0%)	0 (0.0%)	
ASA 47	0 (0.0%)	0 (0.0%)	
ASA 48	0 (0.0%)	0 (0.0%)	
ASA 49	0 (0.0%)	0 (0.0%)	
ASA 50	0 (0.0%)	0 (0.0%)	
ASA 51	0 (0.0%)	0 (0.0%)	
ASA 52	0 (0.0%)	0 (0.0%)	
ASA 53	0 (0.0%)	0 (0.0%)	
ASA 54	0 (0.0%)	0 (0.0%)	
ASA 55	0 (0.0%)	0 (0.0%)	
ASA 56	0 (0.0%)	0 (0.0%)	
ASA 57	0 (0.0%)	0 (0.0%)	
ASA 58	0 (0.0%)	0 (0.0%)	
ASA 59	0 (0.0%)	0 (0.0%)	
ASA 60	0 (0.0%)	0 (0.0%)	
ASA 61	0 (0.0%)	0 (0.0%)	
ASA 62	0 (0.0%)	0 (0.0%)	
ASA 63	0 (0.0%)	0 (0.0%)	
ASA 64	0 (0.0%)	0 (0.0%)	
ASA 65	0 (0.0%)	0 (0.0%)	
ASA 66	0 (0.0%)	0 (0.0%)	
ASA 67	0 (0.0%)	0 (0.0%)	
ASA 68	0 (0.0%)	0 (0.0%)	
ASA 69	0 (0.0%)	0 (0.0%)	
ASA 70	0 (0.0%)	0 (0.0%)	
ASA 71	0 (0.0%)	0 (0.0%)	
ASA 72	0 (0.0%)	0 (0.0%)	
ASA 73	0 (0.0%)	0 (0.0%)	
ASA 74	0 (0.0%)	0 (0.0%)	
ASA 75	0 (0.0%)	0 (0.0%)	
ASA 76	0 (0.0%)	0 (0.0%)	
ASA 77	0 (0.0%)	0 (0.0%)	
ASA 78	0 (0.0%)	0 (0.0%)	
ASA 79	0 (0.0%)	0 (0.0%)	
ASA 80	0 (0.0%)	0 (0.0%)	
ASA 81	0 (0.0%)	0 (0.0%)	
ASA 82	0 (0.0%)	0 (0.0%)	
ASA 83	0 (0.0%)	0 (0.0%)	
ASA 84	0 (0.0%)	0 (0.0%)	
ASA 85	0 (0.0%)	0 (0.0%)	
ASA 86	0 (0.0%)	0 (0.0%)	
ASA 87	0 (0.0%)	0 (0.0%)	
ASA 88	0 (0.0%)	0 (0.0%)	
ASA 89	0 (0.0%)	0 (0.0%)	
ASA 90	0 (0.0%)	0 (0.0%)	
ASA 91	0 (0.0%)	0 (0.0%)	
ASA 92	0 (0.0%)	0 (0.0%)	
ASA 93	0 (0.0%)	0 (0.0%)	
ASA 94	0 (0.0%)	0 (0.0%)	
ASA 95	0 (0.0%)	0 (0.0%)	
ASA 96	0 (0.0%)	0 (0.0%)	
ASA 97	0 (0.0%)	0 (0.0%)	
ASA 98	0 (0.0%)	0 (0.0%)	
ASA 99	0 (0.0%)	0 (0.0%)	
ASA 100	0 (0.0%)	0 (0.0%)	

Table 2 Demographic and Clinical Characteristics by IV Vancomycin Administration

Characteristic	Complete (n=163)	Incomplete (n=298)	P
MI	11 (6.7%)	19 (6.4%)	.841
ASA	1.0 (0.0%)	1.0 (0.0%)	.999
ASA 1	163 (100%)	298 (100%)	
ASA 2	0 (0.0%)	0 (0.0%)	
ASA 3	0 (0.0%)	0 (0.0%)	
ASA 4	0 (0.0%)	0 (0.0%)	
ASA 5	0 (0.0%)	0 (0.0%)	
ASA 6	0 (0.0%)	0 (0.0%)	
ASA 7	0 (0.0%)	0 (0.0%)	
ASA 8	0 (0.0%)	0 (0.0%)	
ASA 9	0 (0.0%)	0 (0.0%)	
ASA 10	0 (0.0%)	0 (0.0%)	
ASA 11	0 (0.0%)	0 (0.0%)	
ASA 12	0 (0.0%)	0 (0.0%)	
ASA 13	0 (0.0%)	0 (0.0%)	
ASA 14	0 (0.0%)	0 (0.0%)	
ASA 15	0 (0.0%)	0 (0.0%)	
ASA 16	0 (0.0%)	0 (0.0%)	
ASA 17	0 (0.0%)	0 (0.0%)	
ASA 18	0 (0.0%)	0 (0.0%)	
ASA 19	0 (0.0%)	0 (0.0%)	
ASA 20	0 (0.0%)	0 (0.0%)	
ASA 21	0 (0.0%)	0 (0.0%)	
ASA 22	0 (0.0%)	0 (0.0%)	
ASA 23	0 (0.0%)	0 (0.0%)	
ASA 24	0 (0.0%)	0 (0.0%)	
ASA 25	0 (0.0%)	0 (0.0%)	
ASA 26	0 (0.0%)	0 (0.0%)	
ASA 27	0 (0.0%)	0 (0.0%)	
ASA 28	0 (0.0%)	0 (0.0%)	
ASA 29	0 (0.0%)	0 (0.0%)	
ASA 30	0 (0.0%)	0 (0.0%)	
ASA 31	0 (0.0%)	0 (0.0%)	
ASA 32	0 (0.0%)	0 (0.0%)	
ASA 33	0 (0.0%)	0 (0.0%)	
ASA 34	0 (0.0%)	0 (0.0%)	
ASA 35	0 (0.0%)	0 (0.0%)	
ASA 36	0 (0.0%)	0 (0.0%)	
ASA 37	0 (0.0%)	0 (0.0%)	
ASA 38	0 (0.0%)	0 (0.0%)	
ASA 39	0 (0.0%)	0 (0.0%)	
ASA 40	0 (0.0%)	0 (0.0%)	
ASA 41	0 (0.0%)	0 (0.0%)	
ASA 42	0 (0.0%)	0 (0.0%)	
ASA 43	0 (0.0%)	0 (0.0%)	
ASA 44	0 (0.0%)	0 (0.0%)	
ASA 45	0 (0.0%)	0 (0.0%)	
ASA 46	0 (0.0%)	0 (0.0%)	
ASA 47	0 (0.0%)	0 (0.0%)	
ASA 48	0 (0.0%)	0 (0.0%)	
ASA 49	0 (0.0%)	0 (0.0%)	
ASA 50	0 (0.0%)	0 (0.0%)	
ASA 51	0 (0.0%)	0 (0.0%)	
ASA 52	0 (0.0%)	0 (0.0%)	
ASA 53	0 (0.0%)	0 (0.0%)	
ASA 54	0 (0.0%)	0 (0.0%)	
ASA 55	0 (0.0%)	0 (0.0%)	
ASA 56	0 (0.0%)	0 (0.0%)	
ASA 57	0 (0.0%)	0 (0.0%)	
ASA 58	0 (0.0%)	0 (0.0%)	
ASA 59	0 (0.0%)	0 (0.0%)	
ASA 60	0 (0.0%)	0 (0.0%)	
ASA 61	0 (0.0%)	0 (0.0%)	
ASA 62	0 (0.0%)	0 (0.0%)	
ASA 63	0 (0.0%)	0 (0.0%)	
ASA 64	0 (0.0%)	0 (0.0%)	
ASA 65	0 (0.0%)	0 (0.0%)	
ASA 66	0 (0.0%)	0 (0.0%)	
ASA 67	0 (0.0%)	0 (0.0%)	
ASA 68	0 (0.0%)	0 (0.0%)	
ASA 69	0 (0.0%)	0 (0.0%)	
ASA 70	0 (0.0%)	0 (0.0%)	
ASA 71	0 (0.0%)	0 (0.0%)	
ASA 72	0 (0.0%)	0 (0.0%)	
ASA 73	0 (0.0%)	0 (0.0%)	
ASA 74	0 (0.0%)	0 (0.0%)	
ASA 75	0 (0.0%)	0 (0.0%)	
ASA 76	0 (0.0%)	0 (0.0%)	
ASA 77	0 (0.0%)	0 (0.0%)	
ASA 78	0 (0.0%)	0 (0.0%)	
ASA 79	0 (0.0%)	0 (0.0%)	
ASA 80	0 (0.0%)	0 (0.0%)	
ASA 81	0 (0.0%)	0 (0.0%)	
ASA 82	0 (0.0%)	0 (0.0%)	
ASA 83	0 (0.0%)	0 (0.0%)	
ASA 84	0 (0.0%)	0 (0.0%)	
ASA 85	0 (0.0%)	0 (0.0%)	
ASA 86	0 (0.0%)	0 (0.0%)	
ASA 87	0 (0.0%)	0 (0.0%)	
ASA 88	0 (0.0%)	0 (0.0%)	
ASA 89	0 (0.0%)	0 (0.0%)	
ASA 90	0 (0.0%)	0 (0.0%)	
ASA 91	0 (0.0%)	0 (0.0%)	
ASA 92	0 (0.0%)	0 (0.0%)	
ASA 93	0 (0.0%)	0 (0.0%)	
ASA 94	0 (0.0%)	0 (0.0%)	
ASA 95	0 (0.0%)	0 (0.0%)	
ASA 96	0 (0.0%)	0 (0.0%)	
ASA 97	0 (0.0%)	0 (0.0%)	
ASA 98	0 (0.0%)	0 (0.0%)	
ASA 99	0 (0.0%)	0 (0.0%)	
ASA 100	0 (0.0%)	0 (0.0%)	

Table 3 Demographic and Clinical Characteristics by IV Vancomycin Administration

Characteristic	Complete (n=163)	Incomplete (n=298)	P
MI	11 (6.7%)	19 (6.4%)	.841
ASA	1.0 (0.0%)	1.0 (0.0%)	.999
ASA 1	163 (100%)	298 (100%)	
ASA 2	0 (0.0%)	0 (0.0%)	
ASA 3	0 (0.0%)	0 (0.0%)	
ASA 4	0 (0.0%)	0 (0.0%)	
ASA 5	0 (0.0%)	0 (0.0%)	
ASA 6	0 (0.0%)	0 (0.0%)	
ASA 7	0 (0.0%)	0 (0.0%)	
ASA 8	0 (0.0%)	0 (0.0%)	
ASA 9	0 (0.0%)	0 (0.0%)	
ASA 10	0 (0.0%)	0 (0.0%)	
ASA 11	0 (0.0%)	0 (0.0%)	
ASA 12	0 (0.0%)	0 (0.0%)	
ASA 13	0 (0.0%)	0 (0.0%)	
ASA 14	0 (0.0%)	0 (0.0%)	
ASA 15	0 (0.0%)	0 (0.0%)	
ASA 16	0 (0.0%)	0 (0.0%)	
ASA 17	0 (0.0%)	0 (0.0%)	
ASA 18	0 (0.0%)	0 (0.0%)	
ASA 19	0 (0.0%)	0 (0.0%)	
ASA 20	0 (0.0%)	0 (0.0%)	
ASA 21	0 (0.0%)	0 (0.0%)	
ASA 22	0 (0.0%)	0 (0.0%)	
ASA 23	0 (0.0%)	0 (0.0%)	
ASA 24	0 (0.0%)		